Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308306229> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4308306229 endingPage "100115" @default.
- W4308306229 startingPage "100115" @default.
- W4308306229 abstract "Allogeneic blood and marrow transplant (BMT) is used to transplant a new immune system in patients with hematologic malignancies or immune-mediated disease. BMT patients require initial immune suppression to prevent graft rejection and graft versus host disease (GVHD). Tacrolimus and cyclosporine are calcineurin inhibitors (CNI) and methotrexate is an antimetabolite used to mitigate this immune response. Tacrolimus has data supporting oral dose variation based on pharmacogenomic (PGx) studies for Intermediate Metabolizers (IM) and Poor Metabolizers (PM) on studies done in kidney transplant patients. There are fewer studies on BMT patients in this field, and even less on the variability of IV to oral conversion dosing and first pass metabolism effect based on PGx profiles. Methotrexate has been shown to have PGx mutations affecting its metabolism at higher dosing used for chemotherapy, but its impact on BMT patient dosing is not well-defined. Based on our study, we found statistically significant variability in Tacrolimus concentration based on drug assay levels compared with dosing for Intravenous (IV) and oral formulation based on PGx predicted phenotypes. We further noted a profound effect on first pass metabolism when transitioning between IV and oral dosing of Tacrolimus based on PGx predicted phenotypes. The average oral dose in predicted IM phenotypes divided by the IV dose was 2.68. For the predicted PM phenotype, the average oral dose divided by the IV dose was 1.18. The p-value in a two-tailed nonparametric T-test with equal variance assessing the conversion factor from IV to oral dosing in predicted IM versus PM phenotypes was significant with a p-value of 0.002. Methotrexate metabolism did not seem to be affected by PGx mutations at the doses used for BMT GVHD prevention." @default.
- W4308306229 created "2022-11-10" @default.
- W4308306229 creator A5007747233 @default.
- W4308306229 creator A5071035927 @default.
- W4308306229 creator A5073162920 @default.
- W4308306229 creator A5091390773 @default.
- W4308306229 date "2022-12-01" @default.
- W4308306229 modified "2023-09-26" @default.
- W4308306229 title "The Impact of Pharmacogenomic CYP3A5 Variants on Calcineurin Inhibitor Metabolism and SLCO1B1 Variants on Methotrexate in Adult Allogeneic BMT Patients" @default.
- W4308306229 cites W1592567691 @default.
- W4308306229 cites W1779344217 @default.
- W4308306229 cites W2005615400 @default.
- W4308306229 cites W2029347729 @default.
- W4308306229 cites W2033139608 @default.
- W4308306229 cites W2063725536 @default.
- W4308306229 cites W2079675818 @default.
- W4308306229 cites W2296407051 @default.
- W4308306229 cites W2605103206 @default.
- W4308306229 cites W2907796455 @default.
- W4308306229 doi "https://doi.org/10.1016/j.tpr.2022.100115" @default.
- W4308306229 hasPublicationYear "2022" @default.
- W4308306229 type Work @default.
- W4308306229 citedByCount "0" @default.
- W4308306229 crossrefType "journal-article" @default.
- W4308306229 hasAuthorship W4308306229A5007747233 @default.
- W4308306229 hasAuthorship W4308306229A5071035927 @default.
- W4308306229 hasAuthorship W4308306229A5073162920 @default.
- W4308306229 hasAuthorship W4308306229A5091390773 @default.
- W4308306229 hasConcept C104317684 @default.
- W4308306229 hasConcept C112705442 @default.
- W4308306229 hasConcept C126322002 @default.
- W4308306229 hasConcept C128057223 @default.
- W4308306229 hasConcept C135763542 @default.
- W4308306229 hasConcept C170734499 @default.
- W4308306229 hasConcept C203014093 @default.
- W4308306229 hasConcept C2777288759 @default.
- W4308306229 hasConcept C2781059491 @default.
- W4308306229 hasConcept C2909675724 @default.
- W4308306229 hasConcept C2911091166 @default.
- W4308306229 hasConcept C55493867 @default.
- W4308306229 hasConcept C55775858 @default.
- W4308306229 hasConcept C71924100 @default.
- W4308306229 hasConcept C86803240 @default.
- W4308306229 hasConcept C8891405 @default.
- W4308306229 hasConcept C92137452 @default.
- W4308306229 hasConcept C98274493 @default.
- W4308306229 hasConceptScore W4308306229C104317684 @default.
- W4308306229 hasConceptScore W4308306229C112705442 @default.
- W4308306229 hasConceptScore W4308306229C126322002 @default.
- W4308306229 hasConceptScore W4308306229C128057223 @default.
- W4308306229 hasConceptScore W4308306229C135763542 @default.
- W4308306229 hasConceptScore W4308306229C170734499 @default.
- W4308306229 hasConceptScore W4308306229C203014093 @default.
- W4308306229 hasConceptScore W4308306229C2777288759 @default.
- W4308306229 hasConceptScore W4308306229C2781059491 @default.
- W4308306229 hasConceptScore W4308306229C2909675724 @default.
- W4308306229 hasConceptScore W4308306229C2911091166 @default.
- W4308306229 hasConceptScore W4308306229C55493867 @default.
- W4308306229 hasConceptScore W4308306229C55775858 @default.
- W4308306229 hasConceptScore W4308306229C71924100 @default.
- W4308306229 hasConceptScore W4308306229C86803240 @default.
- W4308306229 hasConceptScore W4308306229C8891405 @default.
- W4308306229 hasConceptScore W4308306229C92137452 @default.
- W4308306229 hasConceptScore W4308306229C98274493 @default.
- W4308306229 hasFunder F4320306143 @default.
- W4308306229 hasFunder F4320333659 @default.
- W4308306229 hasIssue "4" @default.
- W4308306229 hasLocation W43083062291 @default.
- W4308306229 hasOpenAccess W4308306229 @default.
- W4308306229 hasPrimaryLocation W43083062291 @default.
- W4308306229 hasRelatedWork W1994909423 @default.
- W4308306229 hasRelatedWork W2056593533 @default.
- W4308306229 hasRelatedWork W2150414877 @default.
- W4308306229 hasRelatedWork W2210812892 @default.
- W4308306229 hasRelatedWork W2367645598 @default.
- W4308306229 hasRelatedWork W2407206438 @default.
- W4308306229 hasRelatedWork W2921184558 @default.
- W4308306229 hasRelatedWork W3093139880 @default.
- W4308306229 hasRelatedWork W3150267179 @default.
- W4308306229 hasRelatedWork W2739667538 @default.
- W4308306229 hasVolume "7" @default.
- W4308306229 isParatext "false" @default.
- W4308306229 isRetracted "false" @default.
- W4308306229 workType "article" @default.